https://www.pharmaceutical-technology.com/news/new
Post# of 72447
(Total Views: 263)
Posted On: 03/31/2019 5:50:11 PM
https://www.pharmaceutical-technology.com/new...t-5925184/
Monopar licenses Phase 3 ready Validive OM asset in Sept 2017: $1 million upfront, $15.5 million in regulatory milestones, up to $108 million in sales milestones.
That deal certainly wouldn't bring us very far. I would expect, the way the Leo has been talking, that our deal is going to be a bit juicier than this.
$30-50 million upfront would probably get us around $1/share. $100 million upfront probably closer to $2/share. It's impossible to guess what we're being valued at. We have huge OM potential but our rockstar results were in one arm with 8 ITT/7 PP patients. We probably didn't get BTD.
Leo's plan to restart a shelved program would suggest they are spitballing numbers large enough to facilitate that with potential partners. Whether he's referring to the $30M needed to push B-ABSSSI into phase 3, $13 million for a Kevetrin Oral phase 2, or the $3M to get more preclinical work on other B indications we don't know.
What are you expecting deal wise that is going to make $1/share look like a foolish prediction? $1/share with some cash and a funded trial gets us back in the game. Not to mention a 900% gain and in position for more. Not too shabby for the 60K shares you just bought here.
Monopar licenses Phase 3 ready Validive OM asset in Sept 2017: $1 million upfront, $15.5 million in regulatory milestones, up to $108 million in sales milestones.
That deal certainly wouldn't bring us very far. I would expect, the way the Leo has been talking, that our deal is going to be a bit juicier than this.
$30-50 million upfront would probably get us around $1/share. $100 million upfront probably closer to $2/share. It's impossible to guess what we're being valued at. We have huge OM potential but our rockstar results were in one arm with 8 ITT/7 PP patients. We probably didn't get BTD.
Leo's plan to restart a shelved program would suggest they are spitballing numbers large enough to facilitate that with potential partners. Whether he's referring to the $30M needed to push B-ABSSSI into phase 3, $13 million for a Kevetrin Oral phase 2, or the $3M to get more preclinical work on other B indications we don't know.
What are you expecting deal wise that is going to make $1/share look like a foolish prediction? $1/share with some cash and a funded trial gets us back in the game. Not to mention a 900% gain and in position for more. Not too shabby for the 60K shares you just bought here.
(0)
(1)